STOCK TITAN

Relay Therapeutics (RLAY) 10-K Filings

RLAY NASDAQ

Here are the 10-K annual reports from Relay Therapeutics, Inc. (RLAY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow RLAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLAY filings page.

Rhea-AI Summary

Relay Therapeutics reported another year of heavy investment in R&D while advancing its precision oncology pipeline. For 2025, the company posted a net loss of $276.5 million, an improvement from $337.7 million in 2024, as research and development expenses fell to $261.4 million from $319.1 million after streamlining programs and transferring FGFR2 asset lirafugratinib to Elevar Therapeutics.

License and other revenue reached $15.4 million, mainly from Elevar milestones, while cash, cash equivalents and investments totaled $554.5 million at year-end. Management believes this liquidity can fund operations into 2029, reducing near-term financing pressure.

Relay’s lead candidate zovegalisib, an allosteric, pan‑mutant, isoform‑selective PI3Kα inhibitor, is in a global Phase 3 breast cancer trial (ReDiscover‑2) and a Phase 1/2 vascular anomalies study. In February 2026, the FDA granted Breakthrough Therapy designation for zovegalisib plus fulvestrant in PIK3CA‑mutant HR+/HER2‑ advanced breast cancer, highlighting the program’s regulatory momentum.